Idorsia
The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients.
Launch date
Employees
Market cap
$272m
Enterprise valuation
$1.2b (Public information from Sep 2024)
Share price
CHF1.524 IDIA.SW
Company register number CH-280.3.020.963-7
Allschwil Canton of Basel-Landschaft (HQ)
Financials
Estimates*
| CHF | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 71.8m | 35.3m | 97.1m | 152m | 115m | 204m | 365m |
| % growth | 201 % | (51 %) | 175 % | 57 % | (24 %) | 77 % | 79 % |
| EBITDA | (421m) | (589m) | (783m) | (542m) | (230m) | (288m) | (71.0m) |
| % EBITDA margin | (586 %) | (1666 %) | (806 %) | (356 %) | (199 %) | (141 %) | (19 %) |
| Profit | (445m) | (635m) | (828m) | (298m) | (287m) | (335m) | (93.3m) |
| % profit margin | (620 %) | (1795 %) | (853 %) | (196 %) | (249 %) | (164 %) | (26 %) |
| EV / revenue | 53.4x | 121.4x | 34.7x | 8.9x | 10.1x | 6.7x | 2.9x |
| EV / EBITDA | -9.1x | -7.3x | -4.3x | -2.5x | -5.1x | -4.8x | -15.0x |
| R&D budget | 381m | 414m | 383m | 294m | - | - | - |
| R&D % of revenue | 531 % | 1172 % | 395 % | 193 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
* | N/A | Corporate spinout | |
| N/A | N/A | IPO | |
* | $1.4m | Grant | |
* | N/A | CHF330m | Post IPO Equity |
| N/A | $632m | Post IPO Equity | |
* | N/A | CHF75.0m | Post IPO Debt |
| Total Funding | $1.4m | ||
